HER2‐positive breast cancer brain metastasis: A new and exciting landscape
Abstract Background Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1274 |
| _version_ | 1828216604552331264 |
|---|---|
| author | Alexandra S. Zimmer Amanda E. D. Van Swearingen Carey K. Anders |
| author_facet | Alexandra S. Zimmer Amanda E. D. Van Swearingen Carey K. Anders |
| author_sort | Alexandra S. Zimmer |
| collection | DOAJ |
| description | Abstract Background Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 therapy following a diagnosis of BrM improves outcomes. Previous preclinical data has helped elucidate HER2 brain trophism, the blood‐brain/blood‐tumor barrier(s), and the brain tumor microenvironment, all of which can lead to development of novel therapeutic options. Recent findings Several anti‐HER2 agents are currently available and reviewed here, some of which have recently shown promising effects in BrM patients, specifically. New strategies driven by and focusing on brain metastasis‐specific genomics, immunotherapy, and preventive strategies have shown promising results and are under development. Conclusions The field of HER2+ breast cancer, particularly for BrM, continues to evolve as new therapeutic strategies show promising results in recent clinical trials. Increasing inclusion of patients with BrM in clinical studies, and a focus on assessing their outcomes both intracranially and extracranially, is changing the landscape for patients with HER2+ CNS metastases by demonstrating the ability of newer agents to improve outcomes. |
| first_indexed | 2024-04-12T15:34:31Z |
| format | Article |
| id | doaj.art-5b05926c1c494defbaf4a4b0553ced32 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-04-12T15:34:31Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-5b05926c1c494defbaf4a4b0553ced322022-12-22T03:27:00ZengWileyCancer Reports2573-83482022-04-0154n/an/a10.1002/cnr2.1274HER2‐positive breast cancer brain metastasis: A new and exciting landscapeAlexandra S. Zimmer0Amanda E. D. Van Swearingen1Carey K. Anders2Women's Malignancies Branch National Cancer Institute Bethesda Maryland USADuke Center for Brain and Spine Metastasis Duke Cancer Institute Durham North Carolina USADuke Center for Brain and Spine Metastasis Duke Cancer Institute Durham North Carolina USAAbstract Background Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 therapy following a diagnosis of BrM improves outcomes. Previous preclinical data has helped elucidate HER2 brain trophism, the blood‐brain/blood‐tumor barrier(s), and the brain tumor microenvironment, all of which can lead to development of novel therapeutic options. Recent findings Several anti‐HER2 agents are currently available and reviewed here, some of which have recently shown promising effects in BrM patients, specifically. New strategies driven by and focusing on brain metastasis‐specific genomics, immunotherapy, and preventive strategies have shown promising results and are under development. Conclusions The field of HER2+ breast cancer, particularly for BrM, continues to evolve as new therapeutic strategies show promising results in recent clinical trials. Increasing inclusion of patients with BrM in clinical studies, and a focus on assessing their outcomes both intracranially and extracranially, is changing the landscape for patients with HER2+ CNS metastases by demonstrating the ability of newer agents to improve outcomes.https://doi.org/10.1002/cnr2.1274brain metastasisCNS involvementHER2‐positive breast cancerT‐DM1trastuzumabtucatinib |
| spellingShingle | Alexandra S. Zimmer Amanda E. D. Van Swearingen Carey K. Anders HER2‐positive breast cancer brain metastasis: A new and exciting landscape Cancer Reports brain metastasis CNS involvement HER2‐positive breast cancer T‐DM1 trastuzumab tucatinib |
| title | HER2‐positive breast cancer brain metastasis: A new and exciting landscape |
| title_full | HER2‐positive breast cancer brain metastasis: A new and exciting landscape |
| title_fullStr | HER2‐positive breast cancer brain metastasis: A new and exciting landscape |
| title_full_unstemmed | HER2‐positive breast cancer brain metastasis: A new and exciting landscape |
| title_short | HER2‐positive breast cancer brain metastasis: A new and exciting landscape |
| title_sort | her2 positive breast cancer brain metastasis a new and exciting landscape |
| topic | brain metastasis CNS involvement HER2‐positive breast cancer T‐DM1 trastuzumab tucatinib |
| url | https://doi.org/10.1002/cnr2.1274 |
| work_keys_str_mv | AT alexandraszimmer her2positivebreastcancerbrainmetastasisanewandexcitinglandscape AT amandaedvanswearingen her2positivebreastcancerbrainmetastasisanewandexcitinglandscape AT careykanders her2positivebreastcancerbrainmetastasisanewandexcitinglandscape |